Literature DB >> 9715281

Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors.

J S Zhang1, M Nelson, B McIver, I D Hay, J R Goellner, C S Grant, N L Eberhardt, D I Smith.   

Abstract

We analysed 42 differentiated thyroid tumors including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroid carcinomas (FTC) with 13 microsatellite markers specific for the long arm of human chromosome 7 within 7q31; this region is deleted frequently in several other tumor types. Overall, 20 of the 42 samples analysed (48%) displayed LOH with one or more of the markers tested. LOH was detected most frequently (78%) in FTC, the most malignant of the thyroid tumors. A smallest common deleted region (SCDR) was defined in this tumor type flanked by markers D7S480 and D7S490. This SCDR is distinct from D7S522, the most commonly deleted locus in many other tumors, which was deleted in only one FTC. D7S522 did show LOH in two of six informative PTCs. None of the PTC and only two of the FAs showed LOH in the FTC SCDR. Since FA is considered a premalignant stage of FTC, our results suggest that inactivation of a putative tumor suppressor at 7q31.2 may be acquired during adenoma to carcinoma progression. The absence of LOH at this locus amongst PTC suggests that inactivation of this tumor suppressor is specific for FTC. In conclusion, LOH at 7q31 is a frequent event in differentiated thyroid cancer, and we have defined a 2 cM SCDR specific for FTC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715281     DOI: 10.1038/sj.onc.1201996

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35.

Authors:  Xin Liu; Iona Cheng; Sarah J Plummer; Brian K Suarez; Graham Casey; William J Catalona; John S Witte
Journal:  Prostate       Date:  2010-10-13       Impact factor: 4.104

2.  Mutations in the ST7/RAY1/HELG locus rarely occur in primary colorectal, gastric, and hepatocellular carcinomas.

Authors:  S Yoshimura; T Yamada; S Ohwada; T Koyama; K Hamada; K Tago; I Sakamoto; I Takeyoshi; T Ikeya; F Makita; Y Iino; Y Morishita
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

3.  Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies.

Authors:  Phillippa J Neville; David V Conti; Pamela L Paris; Howard Levin; William J Catalona; Brian K Suarez; John S Witte; Graham Casey
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

4.  Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy.

Authors:  Mary E. Barcus; Celeste N. Powers
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

5.  The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.

Authors:  Luca Lavra; Cinzia Rinaldo; Alessandra Ulivieri; Emidio Luciani; Paolo Fidanza; Laura Giacomelli; Carlo Bellotti; Alberto Ricci; Maria Trovato; Silvia Soddu; Armando Bartolazzi; Salvatore Sciacchitano
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

6.  What is New on Thyroid Cancer Biomarkers.

Authors:  Rosaria M Ruggeri; Alfredo Campennì; Sergio Baldari; Francesco Trimarchi; Maria Trovato
Journal:  Biomark Insights       Date:  2008-04-29

7.  Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis.

Authors:  A Gasbarri; S Sciacchitano; A Marasco; M Papotti; A Di Napoli; A Marzullo; P Yushkov; L Ruco; A Bartolazzi
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.